Silence Therapeutics PLC

This management proposal requests a non-binding, advisory shareholder vote to approve the company’s named executive officers’ compensation as disclosed in the proxy statement. Management frames the proposal as a broad endorsement of the company’s overall compensation philosophy — including base salaries, annual performance cash bonuses tied to a corporate scorecard, and equity-based awards under the 2023 Equity Incentive Plan — aimed at attracting, retaining, and motivating senior executives while aligning their interests with shareholders. The advisory vote is required by SEC rules (Dodd-Frank) but is non-binding; nonetheless, the board and remuneration committee state they will consider the outcome when making future compensation decisions. Key context includes recent management changes in 2025 (CEO transition from Craig Tooman to interim Iain Ross), sizable option grants to executives and directors, and a pay-for-performance structure with both short-term annual bonuses and multi-year equity vesting. The board recommends a vote FOR, arguing that compensation is consistent with market practice and necessary for competitiveness in the biotech sector. Shareholders should view this as an opportunity to express support or concern about the remuneration framework and specific disclosed outcomes (e.g., option grants, severance provisions, clawback policy) without legally binding the board. Given the company’s recent operational progress (clinical milestones, capital management) and the predominance of equity-based incentives, the advisory vote functions as a governance signal that can influence future remuneration calibration. The proposal’s practical impact is governance-oriented: a negative vote would not undo payments but would trigger review and possible adjustments by the remuneration committee. In evaluating the proposal, sophisticated investors should weigh the alignment of disclosed compensation with realized performance metrics (the proxy provides Pay Versus Performance tables), the discretion retained by the Remuneration Committee, and potential governance concerns such as the timing and size of option grants to management during transition periods.

This management proposal asks shareholders to delegate authority to the Audit & Risk Committee to determine the remuneration of the company’s U.K. statutory auditors for the 2026 year. Management is seeking this approval to satisfy the Companies Act requirement that auditor remuneration be fixed by shareholders or in such manner as the shareholders determine, and to streamline the administrative process by vesting that authority in the Audit & Risk Committee. The Audit & Risk Committee, composed solely of independent directors, oversees audit selection, independence, and audit-related fees; the committee has pre-approved PwC’s engagement and asserts that non-audit services provided by PwC are compatible with auditor independence. The board recommends voting FOR on the grounds that delegating remuneration to the Audit & Risk Committee is consistent with good governance, permits timely negotiation with auditors, and aligns responsibility with the committee charged with audit oversight. From a governance perspective, the prudent investor should consider whether the committee’s oversight processes and pre-approval policies sufficiently mitigate conflicts of interest related to non-audit fees (the proxy discloses $219k in 'Other Fees' in 2025). Granting this authority does not change the engagement substantially but provides the committee discretion to set fees in light of work scope and independence considerations. In monitoring implementation, investors should watch for transparency in subsequent disclosures about audit and non-audit fees, and whether the committee exercises this authority consistent with preserving auditor independence and competitive tendering practices.

This management proposal seeks shareholder approval to receive and adopt the company’s 2025 U.K. Annual Report, a procedural requirement under the U.K. Companies Act. While ministerial in nature, the resolution enables shareholders to formally note the audited financial statements and statutory reports prepared by the board and auditors, and provides an opportunity to raise questions at the AGM regarding the published accounts. Management recommends FOR, noting that the Audit & Risk Committee has reviewed the audited financial statements and recommended their inclusion in the Annual Report on Form 10-K. For investors, the substantive value lies in the underlying financial statements, auditor’s report, and the narrative disclosures (including risk and remuneration sections) within the Annual Report rather than in the procedural vote itself. A negative vote would not automatically change past financial statements but would signal significant shareholder concern and prompt board review and engagement. Given the proxy’s disclosure of audit fees, pre-approval policies, and Pay Versus Performance tables, shareholders should consider whether the Annual Report’s narratives and audited figures align with their assessments of company performance and governance. Sophisticated investors will use this vote as a gauge of confidence in financial reporting quality and the board’s stewardship, and will follow up with questions or engagement if outcomes indicate dissatisfaction.

This management proposal requests an advisory shareholder vote to approve the directors’ remuneration report, which details how the board’s remuneration policy was applied in 2025 and how it will be implemented in 2026 (including base salaries, bonuses, equity awards, and severance terms). Though non-binding, the vote is an important governance mechanism under U.K. law and provides shareholders with a formal channel to express views on executive and director pay practices. The remuneration report explains the company’s pay philosophy (balancing fixed pay, annual bonuses, and longer-term equity incentives), discloses 2025 pay outcomes (including significant option grants and a 76% achievement on the corporate scorecard leading to a 41% of salary bonus for the CEO), and outlines severance and clawback arrangements. Management recommends FOR, asserting that the policies and committee oversight align compensation with strategy and shareholder interests; the report also discloses use of external advisors (AON), and the committee’s retained discretion over pay outcomes. Investors should assess whether the disclosed grants and incentive calibrations are commensurate with realized performance, particularly given recent CEO transition and sizable option grants to both executives and non-executive directors. The vote provides a signaling mechanism: a substantial dissent would typically compel the committee to engage with shareholders and potentially revise policy or outcomes. Sophisticated evaluators should consider the mix of cash and equity compensation, governance safeguards (clawback, independent committee), and transparency of performance metrics when judging whether to support this resolution.

This management proposal asks shareholders to approve the continued application of Article 159 of the company’s articles of association — internal takeover protections that apply when the Takeover Code does not apply to the company. The board explains that since the Takeover Panel determined the company is not subject to the Takeover Code, shareholders currently lack certain takeover offer protections; Article 159 embeds certain takeover protections into the articles to address that gap. Management frames this as a protective governance measure that will remain in effect until the next annual general meeting, and recommends a vote FOR. For investors, the substantive questions are whether Article 159’s protections are appropriate in scope and whether they unduly impede change-of-control mechanisms that could maximize shareholder value. Given the company’s current circumstances (delisting from AIM in 2021 and the Takeover Panel’s residency test outcome), the board argues continuation is prudent; however, activists or potential bidders may view entrenched takeover defenses as a barrier to value realization. Sophisticated shareholders should review the exact text of Article 159, consider its interplay with U.K. takeover rules and potential strategic scenarios, and engage with the board if they believe the protections unfairly limit takeover opportunities or shareholder rights.